Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Compass Therapeutics, Inc. - Common Stock
(NQ:
CMPX
)
1.650
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Compass Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
32 Stocks Moving in Tuesday's Pre-Market Session
November 09, 2021
Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
Mid-Morning Market Update: Markets Edge Higher; Pfizer Boosts FY21 Outlook
November 02, 2021
Following the market opening Tuesday, the Dow traded up 0.08% to 35,942.26 while the NASDAQ rose 0.18% to 15,624.19. The S&P also rose, gaining 0.24% to 4,624.80. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
71 Biggest Movers From Yesterday
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
November 01, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
November 01, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
November 01, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 08, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD...
Via
Benzinga
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 01, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
August 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
August 13, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
May 13, 2021
From
Compass Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.